Administrative EyeCare Nov/Dec2017
Regina Boore, MS, BSN, RN, CASC
Mark T. Livingston
In the fall of 2011 more than 20 people were injured when compounding pharmacies repackaged the anti-cancer drug, Avastin, into smaller doses for treating macular degeneration. Many lost their eye-sight and one patient suffered brain damage from the resulting infections.
This article addresses manufacturing and multi-vial use issues with respect to use of compounded sterile preparations (CSPs) in the ASC, including recommendations for standardizing drug pro- tocols so as to reduce liability exposure.